Waning humoral immune responses to inactivated SARS-CoV-2 vaccines in patients with severe liver disease  

作　　者：Zhiwei Chen Yingzhi Zhang Rui Song Lu Wang Xiaoxiao Hu Hu Li Dachuan Cai Peng Hu Xiaofeng Shi Hong Ren 

机构地区：[1]Key Laboratory of Molecular Biology for Infectious Diseases(Ministry of Education),Institute for Viral Hepatitis,Department of Infectious Diseases,the Second Affiliated Hospital of Chongqing Medical University,Chongqing,China

出　　处：《Signal Transduction and Targeted Therapy》2022年第7期2138-2140,共3页信号转导与靶向治疗（英文）

基　　金：supported by the National Science and Technology Major Project of China(2017ZX10202203-007,2017ZX10202203-008,2018ZX10302206-003);a pilot project of clinical cooperation between traditional Chinese and western medicine for significant and complicated diseases of National Administration of Traditional Chinese Medicine:hepatic fibrosis;support of the National Natural Science Foundation of China(81772198),Natural Science Foundation of Chongqing,China(cstc2020jcyj-msxmX0389).

摘　　要：Dear Editor,The Coronavirus disease 2019(COVID-19)pandemic caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is still ongoing around the world.Patients with severe liver disease(SLD),such as compensated cirrhosis(CC),decompensated cirrhosis(DC)or hepatocellular carcinoma(HCC),are highly vulnerable and have worse outcomes from COVID-191.Vaccines are effective measure for the prevention of SARS-CoV-2 infection,severe disease,and mortality.Recent studies have preliminarily described the safety and immunogenicity of SARSCoV-2 vaccines in patients with nonalcoholic fatty liver disease(NAFLD)2,and in patients with chronic hepatitis B virus infection(CHB)3.However,data are limited on the safety and immunogenicity of inactivated vaccines against SARS-CoV-2 in SLD patients.Additionally,the memory B cells(MBCs)responses and immunological memory after vaccination in SLD patients is still unclear.Hence,we aim to explore the safety,antibody responses,and MBCs responses of inactivated vaccines(BBIBPCorV or CoronaVac)in SLD patients through a prospective observational study(NCT05007665).

关 键 词：PATIENTS vaccines PREVENTION 

分 类 号：R373.19[医药卫生—病原生物学] R575[医药卫生—基础医学]